Will the first CRISPR gene therapy for sickle cell disease be approved in Europe by 2027?

This market resolves YES if any CRISPR-based gene therapy for sickle cell disease (such as Casgevy/exagamglogene autotemcel) receives full marketing authorization from the European Medicines Agency before January 1, 2027.

Fecha de Cierre: Jan 1, 2027, 12:00 AM